|
Authors | Year | Sarcoma population | Tissue source | Method of microsatellite assessment | Bethesda consensus panel | Frequency of MSI | Clinical correlation |
|
Wooster et al. [42] | 1994 | Soft-tissue sarcomas () | Unspecified tumor preparation; peripheral blood (genomic control DNA) | PCR; 6% agarose electrophoresis, subcloning, and sequence analysis | 0/5 markers assessed | 11% (2/18) MSI at one loci | Not assessed |
Belchis et al. [37] | 1996 | Osteosarcoma () | FFPE tumor specimens; unspecified normal tissue | PCR; gel electrophoresis; autoradiography | 0/5 markers assessed | 44% (8/18) with MSI at β₯1 loci (2/8 were MSI-H) | Not assessed |
Tarkkanen et al. [43] | 1996 | Bone sarcomas () | Unspecified tumor preparation; peripheral blood (genomic control DNA) | PCR; gel electrophoresis; autoradiography | 0/5 markers assessed | No MSI observed | n/a |
Martin et al. [38] | 1998 | Bone and soft tissue () | Fresh frozen tumor and peripheral blood (genomic control DNA) | PCR; gel electrophoresis; autoradiography | 0/5 markers assessed | 44% (7/16) with MSI at β₯1 loci (3/7 MSI-H) | MSI associated with poor clinical outcome |
Aue et al. [44] | 1998 | Clear cell sarcoma and melanoma () | FFPE specimens (tumor and genomic control DNA) | PCR; gel electrophoresis; autoradiography | 0/5 markers assessed | No MSI observed | Conclude MSI analysis can be used to differentiate CCS from melanoma |
Klinger et al. [39] | 2000 | Chondrosarcoma () | FFPE specimens (tumor and genomic control DNA) | PCR; gel electrophoresis; autoradiography | 0/5 markers assessed | 50% (6/12) with MSI at β₯1 loci (3/6 MSI-H) | Not assessed |
Entz-Werle et al. [45] | 2003 | Osteosarcoma () | Fresh frozen tumor and peripheral blood (genomic control DNA) | Fluorescence-based PCR; automated sequencing | 1/5 markers assessed | No MSI instability observed | n/a |
Ohali et al. [40] | 2004 | Ewing sarcoma () | Fresh frozen tumor and peripheral blood (genomic control DNA) | PCR; gel electrophoresis; autoradiography | 2/5 markers assessed | 48% (11/23) with MSI at β₯1 loci (4/11 MSI-H) | MSI associated with poor clinical outcome |
RuciΕska et al. [41] | 2005 | Soft-tissue sarcomas () | Fresh frozen tumor and peripheral blood (genomic control DNA) | Fluorescence-based PCR; automated sequencing | 1/5 markers assessed | 100% (8/8) of high-grade sarcomas with MSI at β₯1 loci (4/8 MSI-H); No MSI in low-grade sarcomas | Not assessed |
Ebinger et al. [46] | 2005 | Ewing sarcoma () | FFPE specimens (tumor and genomic control DNA) | Unspecified | 5/5 markers assessed | 6% (1/18) with MSI at one loci | Not assessed |
Kawaguchi et al. [56] | 2005 | STS () | Fresh frozen tumor and normal tissue | Fluorescence-based PCR; automated sequencing | 1/5 markers assessed | 25% (10/40) with MSI at β₯1 loci (2/10 MSI-H) | Not assessed |
Entz-WerlΓ© et al. [47] | 2005 | Osteosarcoma ()** same patient cohort as [45] | Fresh frozen tumor and peripheral blood (genomic control DNA) | Fluorescence-based PCR; automated sequencing | 1/5 markers assessed | No MSI instability observed | n/a |
Garcia et al. [48] | 2006 | Clear-cell sarcoma () | FFPE specimens (tumor and genomic control DNA) | Fluorescence-based PCR; automated sequencing | 5/5 markers assessed | 11% (1/9) with MSI at one loci | Conclude MSI analysis can be used to differentiate CCS from melanoma |
Alldinger et al. [49] | 2007 | Ewing sarcoma () | FFPE tumor specimens and peripheral blood (genomic control DNA) | Fluorescence-based PCR; automated sequencing | 5/5 markers assessed | 14% (8/55) with MSI at one loci | MSI not predictive of clinical outcome |
|